The entire Giuseppe Meazza Stadium was holding their breath as Cristiano Ronaldo was about to score the penalty that would make Real Madrid win the Champions League final.
Rio Ferdinand Reaction to Cristiano Ronaldo goal that got Real Madrid winning another Champions League final.
In a post-game interview, Cristiano Ronaldo said he asked his coach Zinédine Zidane to score the last penalty because that would be the winning goal. That's what happened. Atletico Madrid failed to score their fourth penalty shootout, leaving Cristiano Ronaldo with the responsibility of taking the trophy home. He scored.
In the stands watching was the English former professional footballer Rio Ferdinand, which was Ronaldo's former Manchester United teammate. Mr. Ferdinand couldn't hide his excitation and shouted "he deserves that!" just after the player scored the winning goal.
Mr. Ferdinand uploaded the video of him watching Cristiano Ronaldo’s penalty to Instagram and said:
"When you are as committed to working as hard as Cristiano does to do what he does year in year out at the highest level, you deserve some fortune/luck. He didn't have his finest 120mins in a Real Madrid shirt, but he got the fortune to be the man with the opportunity to score the winning penalty. I was always told as a kid - you work hard, you get lucky!
Lucky is to get the opportunity to take the winning penalty, after that it's down to nerve, technique & composure. Game won!"
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
